Clinical trials examining the therapeutic benefit of omega-3 polyunsaturated fatty acids (ω-3 PUFAs) on nonalcoholic fatty liver disease (NAFLD) have reported inconsistent results. This study was a meta-analysis of trials (1). The results showed that eighteen studies involving 1424 patients were included. The authors found a significant benefit for ω-3 PUFAs vs control for liver fat, alanine aminotransferase, aspartate aminotransferase, γ-glutamyl transferase, triglycerides, insulin resistance, and glucose. However, there was significant interstudy heterogeneity. The authors conclude that ω-3 PUFA supplementation may decrease liver fat and hepatic enzyme parameters.